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Many forms of leukaemia are caused by chromosomal translocations, which 
result in specific and characteristic genomic sequences.  Where these sequences are 
unique to the leukaemic cells, they represent good candidates for targeting by sequence-
specific techniques, such as RNA-Interference (RNAi).  RNAi is a mechanism inherent 
in eukaryotic cells which silences target mRNAs based on homology to a dsRNA 
template.  This template may be introduced artificially by a number of methods, and so 
this mechanism can be manipulated to regulate the expression of target genes.  One of 
the most efficient methods of introducing RNAi templates is by expression of short-
hairpin RNA (shRNA) cassettes from DNA plasmids or vectors.
Lentiviral vectors are based on viruses that integrate into the DNA of the host 
cell, and are a highly efficient class of vectors for transducing and providing stable 
transgene expression in a range of cell types.  They are particularly effective at
tansducing haematopoietic cells, which have proven difficult to transduce by other 
methods.  By fine-tuning the methods of vector production and transduction, a range of 
human leukaemic cells lines were able to be transduced with unprecedented efficiency 
in the present study.  Lentiviral transduction was combined with rapid puromycin 
selection to generate a pure population of transduced cells with minimal expansion of 
the cell population.
The strategy of expressing shRNAs from retroviral and lentiviral vectors 
combined with puromycin selection was used to target three well-characterised fusion 
genes; Bcr-Abl, PML/RARα and RUNX1/ETO, in three human leukaemic cell lines.  In 
two of these, the shRNA was able to efficiently and effectively down-regulate the target 
mRNA, and inhibit the proliferation of the transduced leukaemic cells.  In the third case, 
RUNX1/ETO, no effective shRNA design could be identified.
Finally, concerns over the safety of integration targeting by current gene therapy 
vectors motivated an investigation of the activity of a novel integrase enzyme from the 
Ty3 retrotransposon found in yeast.  In yeast cells, the integration-mediating enzyme of 
this retrotransposon has very specific targeting characteristcs, which, if retained in 
human cells, would provide a very safe gene therapy vector.  It was found that this 
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